Assessing change in Anti-Mullerian Hormone associated with surgical excision vs conservative management of endometrioma

Not Applicable

Recruiting

• Conditions: Endometriosis; Endometrioma; Reproductive Health and Childbirth - Other reproductive health and childbirth disorders

• Registration Number: ACTRN12620001201965
• Lead Sponsor: Keryn Harlow

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-11-12
• Last Update Posted: 14 March 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 572

Inclusion Criteria

Women aged 25-37 presenting to: general gynaecology outpatient clinic or Reproductive Services Unit at The Royal Women’s Hospital, or to a level 5 or 6 laparoscopic accredited gynaecologist or fertility specialist at Ramsay Health, Epworth Healthcare, Melbourne IVF or NewLife IVF, or the Endometriosis Centre at Hadassah-Hebrew University Medical Centre in Israel with an ultrasound (USS) diagnosis of endometrioma defined as: the presence of one or more ovarian cysts equal to or greater than 2cm diameter with regular margins and ground glass echogenicity that does not reduce in size over 4 or more weeks.

Exclusion Criteria

Endometrioma <2 cm diameter- these patients are more likely to be managed conservatively
Factors that can affect ovarian reserve, including previous ovarian surgery, oophorectomy, chemotherapy
Suspicion of malignancy- and will therefore be offered surgery
Inability to provide informed consent
Non-English speaking
Previous or planned hysterectomy- as hysterectomy is known to reduce AMH

Study & Design

• Study Type: Observational
• Study Design: Not specified